RESEARCH & DEVELOPMENT
Our pipeline of product candidates represents an important opportunity to improve the treatment of patients experiencing CINV. We use proprietary transdermal technology with products that build on the current treatment guidelines.
The company is reformulating generic medicines that are well characterized and have a long and robust medical history. This allows for a shortened development timeline and significantly reduced financial investment and risk by leveraging the 505(b)2 regulatory pathway.